Increased GLP-1 Response after Gavage-Administration of Glucose in UCP2-deficient Mice

H. Zhang; J. Li; Z. Li; Y. Luo

doi:10.1055/s-0031-1298017

Hormone and Metabolic Research, Table of Contents

Horm Metab Res 2012; 44(02): 86-90
DOI: 10.1055/s-0031-1298017

Original Basic

Increased GLP-1 Response after Gavage-Administration of Glucose in UCP2-deficient Mice

H. Zhang

¹The First Affiliated Hospital of Nanjing Medical University Nanjing, Jiangsu, China

,

J. Li

²The Jiangsu Diabetes Center, State Key Laboratory of Pharmaceutical Biotechnology, School of Biological Sciences, Nanjing University, Nanjing, Jiangsu, China

,

Z. Li

¹The First Affiliated Hospital of Nanjing Medical University Nanjing, Jiangsu, China

,

Y. Luo

²The Jiangsu Diabetes Center, State Key Laboratory of Pharmaceutical Biotechnology, School of Biological Sciences, Nanjing University, Nanjing, Jiangsu, China

› Author Affiliations

Abstract

Although it has been widely reported that endogenous level of GLP-1 can be enhanced by various secretagogues, the mechanism of GLP-1 secretion in vivo is still not fully understood. In the present study, we assessed the possible effect of uncoupling protein 2 (UCP2) on GLP-1 secretion in gut. The levels of plasma GLP-1(7–36) amide/(7–37) in UCP2-deficient mice and wild-type mice were measured by applying ELISA technique. UCP2 mRNA and protein levels were detected in the gastrointestinal tract by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blot analysis, respectively. The plasma GLP-1 levels in C57BL/6J mice had significantly increased to 6.9 pM (n=8, p<0.001) at 15 min after gavage-administration of glucose (2 g glucose/kg body weight), approximately 2-fold, compared with control group. Plasma GLP-1 levels were also significantly elevated at 30 min (p<0.001), but nearly returned to baseline levels at 60 min. UCP2-deficient mice had higher level of GLP-1 at various time points after administration of glucose (UCP2-deficient mice vs. wild type littermates, 15 min, 9.3±0.9 vs. 6.9±0.3, p<0.001; 30 min, 7.9±0.3 vs. 5.6±0.4, p<0.001; 60 min, 4.9±0.1 vs. 3.3±0.1, p<0.01). UCP2-deficient mice increased GLP-1 response to gavage-administration of glucose. Plasma GLP-1 level was not significantly altered after gavage-administration of saline. This study showed that plasma GLP-1 level increased after gastric glucose challenge, and UCP2 maybe serve as a negative regulator in glucose-induced GLP-1 secretion in mouse gut tract.

Key words

UCP2 - GLP-1 - gut - glucose - UCP2-deficient mice

Full Text

References

References
1 Elrick H, Stimmler L, Hlad Jr CJ, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964; 24: 1076-1082
2 McIntyre N, Holdsworth CD, Turner DS. Intestinal factors in the control of insulin secretion. J Clin Endocrinol Metab 1965; 25: 1317-1324
3 Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967; 46: 1954-1962
4 Ranganath L, Schaper F, Gama R, Morgan L, Wright J, Teale D. Effect of glucagon on carbohydrate-mediated secretion of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7–36 amide) (GLP-1). Diabetes Metab Res Rev 1999; 15: 390-394
5 Holst JJ, Ørskov C, Vagn Nielsen O, Schwartz TW. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 1987; 211: 169-174
6 Eissele R, Göke R, Willemer S, Harthus HP, Vermeer H, Arnold R, Göke B. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig, and man. Eur J Clin Invest 1992; 22: 283-291
7 Larsson LI, Holst J, Hakanson R, Sundler F. Distribution and properties of glucagon immuno-reactivity in the digestive tract of various mammals: an immunohistochemical and immunochemical study. Histochemistry 1975; 44: 281-290
8 Damholt AB, Kofod H, Buchan AM. Immunocytochemical evidence for a paracrine interaction between GIP and GLP-1-producing cells in canine small intestine. Cell Tissue Res 1999; 298: 287-293
9 Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-3723
10 Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, Bloom SR. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9–39. Diabetes 1999; 48: 86-93
11 Tseng CC, Zhang XY, Wolfe MM. Effect of GIP and GLP-1 antagonists on insulin release in the rat. Am J Physiol 1999; 276 (6 Pt 1) E1049-E1054
12 Rorsman P. The pancreatic β-cell as a fuel sensor: an electrophysiologist’s viewpoint. Diabetologia 1997; 40: 487-495
13 Simpson AK, Ward PS, Wong KY, Collord GJ, Habib AM, Reimann F, Gribble FM. Cyclic AMP triggers glucagon-like peptide-1 secretion from the GLUTag enteroendocrine cell line. Diabetologia 2007; 50: 2181-2189
14 Herrmann C, Göke R, Richter G, Fehmann HC, Arnold R, Göke B. Glucagon-like peptide-1 and glucose dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995; 56: 117-126
15 Ritzel U, Fromme A, Ottleben M, Leonhardt U, Ramadori G. Release of glucagon-like peptide-1 (GLP-1) by carbohydrates in the perfused rat ileum. Acta Diabetol 1997; 34: 18-21
16 Gribble FM, Williams L, Simpson AK, Reimann F. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 2003; 52: 1147-1154
17 Margolskee RF, Dyer J, Kokrashvili Z, Salmon KS, IIegems E, Daly K, Maillet EL, Ninomiya Y, Mosinger B, Shirazi-Beechey SP. T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter1. Proc Natl Acad Sci USA 2007; 104: 15075-15080
18 Rozengurt E, Sternini C. Taste receptor signaling in the mammalian gut. Curr Opin Pharmacol 2007; 7: 557-562
19 Donley VR, Hiskett EK, Kidder AC, Schermerhorn T. ATP-sensitive potassium channel (K_ATP channel) expression in the normal canine pancreas and in canine insulinomas. BMC Vet Res 2005; 1: 8
20 Nielsen LB, Ploug KB, Swift P, Ørskov C, Jansen-Olesen I, Chiarelli F, Holst JJ, Hougaard P, Pörksen S, Holl R, de Beaufort C, Gammeltoft S, Rorsman P, Mortensen HB, Hansen L. Hvidøre Study Group. Co-localisation of the Kir6.2/SUR1 channel complex with glucagon-like peptide-1 and glucose-dependent insulinotrophic polypeptide expression in human ileal cells and implications for glycaemic control in new onset type 1 diabetes. Eur J Endocrinol 2007; 156: 663-671
21 Jezek P. Possible physiological roles of mitochondrial uncoupling proteins – UCPn. Int J Biochem Cell Biol 2002; 34: 1190-1206
22 Diao J, Allister EM, Koshkin V, Lee SC, Bhattacharjee A, Tang C, Giacca A, Chan CB, Wheeler MB. UCP2 is highly expressed in pancreaticβ-cells and influences secretion and survival. Proc Natl Acad Sci USA 2008; 105: 12057-12062
23 Nedergaard J, Cannon B. The novel ‘uncoupling proteins’ UCP2 and UCP3: what do they really do? Pros and cons for suggested functions. Exp Physiol 2003; 88: 65-84
24 Mattiasson G, Sullivan PG. The emerging functions of UCP2 in health, disease, and therapeutics. Antioxid Redox Signal 2006; 8: 1-38
25 Ahrén B, Larsson H, Holst JJ. Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance. Eur J Endocrinol 1997; 137: 127-131
26 Ahrén B. Glucagon-like peptide 1 (GLP-1) – a gut hormone of potential interest in the treatment of diabetes. Bioessays 1998; 20: 642-651
27 Zhang CY, Baffy G, Perret P, Krauss S, Peroni O, Grujic D, Hagen T, Vidal-Puig AJ, Boss O, Kim YB, Zheng XX, Wheeler MB, Shulman GI, Chan CB, Lowell BB. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell 2001; 105: 745-755
28 Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K, Egan JM. Human duodenal enteroendocrine cells: source of both incretions peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 2006; 290: E550-E559
29 Schirra J, Katschinski M, Weidmann C, Schäfer T, Wank U, Arnold R, Göke B. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 1996; 97: 92-103
30 Balks HJ, Holst JJ, von zur Mühlen A, Brabant G. Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors. J Clin Endocrinol Metab 1997; 82: 786-790
31 Kim BJ, Carlson OD, Jang HJ, Elahi D, Berry C, Egan JM. Peptide YY is secreted after oral glucose administration in a gender-specific manner. J Clin Endocrinol Metab 2005; 90: 6665-6671